Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOH1996 in Relapsed/Refractory Acute Myeloid Leukemia
NCT06763341Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aoh1996 in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoints: Incidence of dose limiting toxicity at 28 days and Incidence of adverse events up to 2 years. Started Jul 2025; status: recruiting.
02
Drugs
aoh1996
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06763341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763341.